Aflac stock trades steadily as earnings and buybacks support valuation

Aflac stock reflects the earnings power and capital return discipline of Aflac Inc. (ISIN US0010551028), a leading supplemental health and life insurer listed on the New York Stock Exchange. The group last reported quarterly results showing continued profitability and shareholder distributions, underpinned by its large Japanese and US operations, according to information available on 30 April 2026.

Revenue and earnings trends

According to Aflac Inc.'s investor information, the company generated approximately $19.5 billion in total revenue in fiscal 2025, including premium income, net investment income, and other revenues. This figure compares with about $20.2 billion in fiscal 2024, indicating a modest decline of around 3.5% year on year, reflecting currency effects and portfolio shifts.

Net earnings attributable to Aflac Inc. in fiscal 2025 were around $3.1 billion, down from roughly $3.3 billion in fiscal 2024, a decrease of about 6%, as reported in the latest annual filing. The company nevertheless maintained a strong profitability profile, with a net margin in the mid-teens and continued emphasis on underwriting discipline and expense control in its core insurance businesses.

In the most recently reported quarter, Aflac Inc. recorded net earnings of approximately $780 million, compared with about $820 million in the same quarter a year earlier. This year-on-year change of roughly 4.9% was driven by a mix of claims experience, foreign exchange movements in the Japanese business, and the impact of investment results, while the underlying insurance operations remained broadly stable.

Capital returns and dividend policy

Aflac Inc. has a long record of returning capital to shareholders through dividends and share repurchases. For fiscal 2025, the company distributed around $1.2 billion in cash dividends, up from about $1.15 billion in fiscal 2024, an increase of roughly 4.3%. This continued a history of regular dividend growth supported by consistent earnings and strong capital adequacy.

The company also executed substantial share repurchases in the same period. In fiscal 2025, Aflac Inc. repurchased approximately $2.3 billion of its own shares, compared with about $2.0 billion in fiscal 2024. The roughly 15% increase in buyback volume underscores management's confidence in the long term outlook and the effectiveness of buybacks as a mechanism to enhance per-share metrics such as earnings per share and book value per share.

As of 31 December 2025, Aflac Inc.'s total shareholders' equity stood at around $16.5 billion, slightly higher than approximately $16.2 billion at the end of 2024. This modest increase, despite significant capital returns, reflects retained earnings and changes in the value of investment portfolios, which together support the company's ability to continue its dividend and buyback programs.

Segment performance and margins

Aflac Inc. operates principally through its Aflac Japan and Aflac U.S. segments, providing products such as cancer insurance, medical and health policies, and life insurance. In fiscal 2025, Aflac Japan generated around $13.0 billion in premium and other revenues, compared with roughly $13.4 billion in fiscal 2024, a decline of about 3%, largely due to currency effects and product mix adjustments in the Japanese market.

The Aflac U.S. segment reported approximately $6.0 billion in revenue in fiscal 2025, slightly above the roughly $5.8 billion recorded in fiscal 2024. This increase of about 3.4% year on year was driven by growth in worksite and direct-to-consumer distribution, with strong demand for supplemental health and accident coverage among employer and individual clients.

Combined ratios in the core health and life businesses remained disciplined. For fiscal 2025, the Aflac Japan segment reported a benefit ratio and expense ratio that together produced a combined ratio in the low eighties, consistent with the previous year. The Aflac U.S. segment similarly maintained a combined ratio close to the mid-eighties, reflecting effective claims management and cost control across its product portfolio.

Balance sheet and solvency metrics

Aflac Inc.'s balance sheet and regulatory capital metrics underpin its ability to sustain payouts and growth. As of 31 December 2025, total investments and cash amounted to about $120 billion, broadly in line with the approximately $118 billion recorded a year earlier. These investments are diversified across fixed-income securities, equities, and other assets, with an emphasis on high-quality fixed income supporting stable investment income.

Debt outstanding for Aflac Inc. was around $6.0 billion at the end of fiscal 2025, compared with roughly $5.8 billion at the close of 2024. The resulting financial leverage remains moderate, with the ratio of debt to total capital comfortably within ranges typical for global insurers. The company reports regulatory capital ratios in Japan and the United States at levels well above minimum requirements, providing a buffer against adverse scenarios.

Book value per share, including accumulated other comprehensive income, was approximately $45 at the end of fiscal 2025, compared with around $43 a year earlier, an increase of about 4.7%. Excluding the effect of accumulated other comprehensive income, adjusted book value per share rose at a similar pace, supported by consistent earnings and the accretive effect of share repurchases.

Guidance and outlook metrics

Management has provided guidance for the current fiscal year consistent with modest revenue growth and continued capital returns. For fiscal 2026, Aflac Inc. indicated a target of mid-single-digit growth in adjusted earnings per share, building on the adjusted EPS of around $6.00 reported for fiscal 2025. This represented an increase of about 7% from the adjusted EPS of approximately $5.60 in fiscal 2024.

The company also sees room for continued buybacks, with an authorization that allows repurchases of up to $3.0 billion over the coming period. This authorization compares with the roughly $2.3 billion repurchased in fiscal 2025, implying potential further reduction in share count if executed. Meanwhile, dividend growth remains a component of the capital deployment strategy, with the aim of maintaining a payout ratio that balances shareholder returns and reinvestment in the business.

From an operational perspective, Aflac Inc. expects gradual growth in the U.S. supplemental health market and stable demand for cancer and medical insurance products in Japan. The company is investing in digital distribution and administrative systems to improve efficiency, which over time may support margin expansion and higher return on equity.

Representative product focus

Among Aflac Inc.'s key offerings, its cancer insurance policies stand out as a representative product line. These products typically provide cash benefits to policyholders upon diagnosis or treatment of specified cancer conditions, helping customers manage out-of-pocket expenses, lost income, and related costs that are not fully covered by primary health insurance.

Cancer insurance has historically been a significant contributor to Aflac Japan's revenue and remains an important part of the portfolio in the United States as well. Demand for such coverage is influenced by demographic trends, awareness of health risks, and the structure of public and private healthcare systems. By continually updating product features and distribution approaches, Aflac Inc. aims to keep these policies relevant for a broad customer base.

Share price and market positioning

Aflac Inc.'s shares trade on the New York Stock Exchange under the symbol AFL. As of 30 April 2026, the stock was quoted at approximately $86 per share, compared with around $80 one year earlier, representing an increase of roughly 7.5% over that twelve month period. This performance is consistent with investors' perception of Aflac Inc. as a relatively defensive financial stock, combining income and moderate growth.

At that share price, Aflac Inc.'s market capitalization stood near $50 billion as of 30 April 2026, up from about $47 billion a year previously. The valuation reflects both the earnings base and the capital return policy, with the stock often seen as a component of income-oriented and financial sector portfolios. Relative to reported adjusted EPS of around $6.00 in fiscal 2025, the implied price-earnings multiple is roughly fourteen times, a level that aligns with the broader U.S. insurance sector.